Analyst
Equibles does not estimate personal net worth.
Alexey Aleshin has spoken on 5 earnings calls across 1 company, most recently for Natera, Inc. on August 6, 2026. The companies whose calls Alexey Aleshin spoke on are classified in the Healthcare sector.
“I want to spend a couple of minutes on the depth of the clinical evidence engine we've built behind Signatera and why we think it's such a durable advantage. If you look at slide 13, you can see the shape of that engine.”
“TOMER, PAN CANCER MRD, PHASE-BARIAN TECHNOLOGY, REAL-WORLD EVIDENCE, AND TRIALS IN PROGRESS. THAT LEVEL OF OUTPUT MATTERS BECAUSE IT SHOWS SIGNATER IS NOT A SINGLE TUMOR, SINGLE USE CASE, OR SINGLE STUDY STORY.”
“We continue to make steady progress on our ECD program. We have now consented over 3,500 patients for our preceded CRC study, which is a prospective average risk colonoscopy matched trial.”
“I would also just highlight, you know, I think there are more and more smaller histologies, like we highlighted sarcoma, where we are starting to see data mature.”
“I want to start by highlighting the CalGB SWOG 80702 study, the results of which were presented in an oral session at this year's ASCO GI conference. Signotera was utilized to examine in a pre-specified manner the tumor and plasma from around 1,000 stage 3 colorectal cancer patients in this randomized cohort.”
NTRA
Diagnostics & Research · Healthcare
